Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of TQH3906 in adults with moderate-to-severe plaque psoriasis
CTR20262797Phase 3Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of TQH3906 in plaque psoriasis, sponsored by Nanjing Shunxin Pharmaceutical. Started Sep 2026; status: active.
02
Drugs
TQH3906
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20262797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262797.